Home / Research / Manufacturers / bioMerieux Medical-device intelligence
bioMerieux: FDA clearances and recalls Research bioMerieux in public FDA records: applicant and recalling-firm names, product codes, clearance history, and recall records.
Names and coverage This profile groups matching applicant and recalling-firm names found in covered FDA records. It does not imply a complete corporate family, current ownership, or every product marketed under a brand.
Names observed in the source
bioMerieux Biomerieux BIOMERIEUX Capitalization and punctuation variants are normalized. Customer-entered watchlist aliases remain private.
Product codes in this company’s records Record activity in this scope 3 clearance records and 17 recall records in the covered releases, across 1 source company names and 9 product codes. Dated history runs from Jul 31, 2003 to Mar 26, 2026.
Monthly counts through October 2026 Month 510(k) decisions Recall initiations October 2025 0 0 November 2025 0 0 December 2025 0 0 January 2026 0 0 February 2026 0 0 March 2026 1 0 April 2026 0 0 May 2026 0 0 June 2026 0 0 July 2026 0 0 August 2026 0 0 September 2026 0 0 October 2026 0 0
Product codes represented Code and FDA device name Clearances Recalls JWY · Manual Antimicrobial Susceptibility Test Systems 1 9 GJA · Test, Thrombin Time 0 2 GJS · Test, Time, Prothrombin 0 2 JPA · System, Multipurpose For In Vitro Coagulation Studies 0 1 LFZ · Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus 0 1 LJC · Enzyme Linked Immunoabsorbent Assay, (Chlamydiae Group) 0 1 LON · System, Test, Automated, Antimicrobial Susceptibility, Short Incubation 1 0 LYR · Helicobacter Pylori 1 0 MDB · System, Blood Culturing 0 1
All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.
Clearances and recall records 20 matching records Device / record Company in FDA record Source Source date VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) K260281 · LONBIOMERIEUX 510(k) Mar 26, 2026FDA decision date Etest Piperacillin/tazobactam (4 ug/mL) PTc0.016-256-pack of 30 tests WW
Etest is a quantitative technique for determining the antimicrobial sus… Z-0439-2016 · JWYBiomerieux Recall Dec 23, 2015FDA classification date Etest PIP/TAZO/CON-4 PTC 256 -pack of 30 tests US.
Etest is a quantitative technique for determining the antimicrobial susceptibility of Gram-ne… Z-0440-2016 · JWYBiomerieux Recall Dec 23, 2015FDA classification date Etest PIP/TAZO/CON-4 PTC 256 - Foam of 100 tests WW.
Etest is a quantitative technique for determining the antimicrobial susceptibility of Gram-… Z-0441-2016 · JWYBiomerieux Recall Dec 23, 2015FDA classification date Etest PIP/TAZO/CON-4 PTC 256 - Foam of 100 tests US.
Etest is a quantitative technique for determining the antimicrobial susceptibility of Gram-… Z-0442-2016 · JWYBiomerieux Recall Dec 23, 2015FDA classification date VIDAS H. pylori IgG, VIDAS 3, VIDAS Lyme IgG II, VIDAS RUB IgG, VIDAS TOXO M, VIDAS Human Chorionic Gonadotropin, VIDAS T4, VIDAS Testosterone, V… K141133 · LYRBIOMERIEUX 510(k) Jul 9, 2015FDA decision date Etest Ceftaroline (CPT32) WW B30.
Etest (Antimicrobial Susceptibility Testing) is a quantitative technique for determining the antimicrobial sus… Z-0230-2015 · JWYBiomerieux Recall Nov 19, 2014FDA classification date Etest Ceftaroline (CPT32) WWB100.
Etest (Antimicrobial Susceptibility Testing) is a quantitative technique for determining the antimicrobial sus… Z-0231-2015 · JWYBiomerieux Recall Nov 19, 2014FDA classification date Etest Ceftaroline (CPT32) US B30.
Etest (Antimicrobial Susceptibility Testing) is a quantitative technique for determining the antimicrobial sus… Z-0232-2015 · JWYBiomerieux Recall Nov 19, 2014FDA classification date Etest Ceftaroline (CPT32) US B100.
Etest (Antimicrobial Susceptibility Testing) is a quantitative technique for determining the antimicrobial su… Z-0233-2015 · JWYBiomerieux Recall Nov 19, 2014FDA classification date Etest Ceftaroline (CPT32) US B30.
Etest (Antimicrobial Susceptibility Testing) is a quantitative technique for determining the antimicrobial sus… Z-0234-2015 · JWYBiomerieux Recall Nov 19, 2014FDA classification date ETEST TOBRAMYCIN 0.016-256 UG/ML AND 0.064-1024 UG/ML K102668 · JWYBIOMERIEUX 510(k) Nov 17, 2010FDA decision date BacT/ALERT(BTA) Classic instruments. Z-0456-05 · MDBbioMerieux Recall Feb 1, 2005FDA classification date MDA Fibriquik, bioMeriux, Inc., Box 15969, Durham, North Carolina 27704-0969 Z-0053-05 · GJAbioMerieux Recall Oct 28, 2004FDA classification date Fibriquik, bioMeriux, Inc., Box 15969, Durham, North Carolina 27704-0969 Z-0054-05 · GJAbioMerieux Recall Oct 28, 2004FDA classification date The MDA system with MDA Antithrombin III
MDA Heparin Z-0043-05 · JPAbioMerieux Recall Oct 23, 2004FDA classification date VIDAS CMV IgG Assay Z-1047-04 · LFZbioMerieux Recall Jul 20, 2004FDA classification date VIDAS Chlamydia Assay (CHL) for In-Vitro Diagnostic Use
Product Number: 30101 Z-1209-03 · LJCbioMerieux Recall Oct 15, 2003FDA classification date Simplastin L, Prothrombin Time test, 10 vials (20 ml each), Product Number 259553, bioMerieux, Z-1238-03 · GJSbioMerieux Recall Oct 15, 2003FDA classification date MDA Simplastin L, Product number 252555, 10 vials, 40 ml ea (400 test each), bioMerieux Inc., Box 15969 Durham, North Carolina 27704-0969. Z-1239-03 · GJSbioMerieux Recall Oct 15, 2003FDA classification date
Device classifications FDA dataset: Nov 9, 2026
Last successful check: Nov 22, 2026
Source classifications may change.
510(k) clearances FDA dataset: Nov 9, 2026
Last successful check: Nov 22, 2026
FDA publishes this dataset monthly.
Recall records FDA dataset: Nov 19, 2026
Last successful check: Nov 22, 2026
FDA publishes this dataset weekly.
Keep this research moving. Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.
Start a 14-day free trial ↗